NovoCure (NASDAQ:NVCR) PT Raised to $22.00

NovoCure NASDAQNVCR is a medical equipment provider that specializes in the development and sale of its proprietary technology for the treatment of cancer. The company's technology, called Tumor Treating Field (TTFields), uses electromagnetic fields to treat tumors without surgery or radiation therapy.

On Thursday, stock analysts at HC Wainwright issued a research report on NovoCure NASDAQNVCR and raised their target price from $21.00 to $22.00. This means that they believe the stock is undervalued and has the potential for growth. The brokerage currently has a "buy" rating on the company's stock, indicating that they recommend investors buy shares of NovoCure NASDAQNVCR.

The target price set by HC Wainwright indicates a potential upside of 44.55% from the current stock price. This means that if the stock reaches its target price, it will have increased in value by 44.55%.

It's worth noting that stock prices can be volatile and subject to change based on various factors such as market conditions, company performance, and news events. Therefore, it's important for investors to do their own research and consider seeking advice from a financial advisor before making any investment decisions.